Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genomic Solutions-naz{GNSL} -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (70)	6/8/2001 1:53:54 PM
From: tuck	Read Replies (1) \| Respond to of 93

smh, A minor win for GNSL. I might see if I can get prices on those components to see just how minor it is or isn't. At least this is some evidence that PKI is doing something productive now that the relationship has been normalized. siliconinvestor.com The stock is over $5 as I type for the first time in a while. Good news for my Mom and for Trickle, bad news for BLUE HP, which was vulturishly hoping for one last bite below $4. Cheers, Tuck

To: smh who wrote (70)	7/5/2001 9:30:31 AM
From: tuck	Respond to of 93

GNSL warns: >>ANN ARBOR, Mich., July 5 /PRNewswire/ -- Genomic Solutions Inc. (Nasdaq: GNSL - news), a leading, worldwide supplier of automated solutions for genomic and proteomic research, announced today that it expects revenues for the second quarter ended June 30, 2001 to be between $4.5 and $4.6 million, or about 4% more than the first quarter of 2001 and also slightly higher than the second quarter of 2000. The Company expects to report a net loss per share between $0.11 to $0.13 as compared to $0.12 in the first quarter of 2001 and $0.17 for second quarter of 2000. These preliminary financial estimates are subject to final accounting and review processes, and therefore, could change. ``While the company grew revenue during the quarter, multiple market factors, driven by the current economic climate, led to the unanticipated weakness in orders and lower than forecasted revenue.'' said Jeffrey S. Williams, President and CEO. ``The lower than expected growth is attributed, at least in part, to our customers postponing purchases until later this year.'' ``We typically experience a spike in orders near the end of the quarter. Our order data compiled late in the quarter suggests that a number of our customers have delayed purchasing decisions for various reasons, including the current economic conditions,'' noted Michael P. Kurek, Ph.D., Executive Vice President of Sales and Customer Service. ``While our financial results for the quarter were slightly below our expectations, we remain confident about our longer-term growth prospects and the fundamental strength of the genomic and proteomic research marketplace,'' Mr. Williams added. ``As planned, we introduced several innovative products late in the second quarter, including the Investigator(TM) ProPREP Protein Digestion and Mass Spec Preparation Station, GeneTAC(TM) UC-4 Microarray Analyzer, and several new pre-printed GeneMAP(TM) arrays. We expect all of these new products to contribute to revenue growth in the third and fourth quarters of this year. In addition, our operating expenses remain in check, our pipeline of expected sales orders for the second half of the year is at a record level, and our distribution partner, PerkinElmer Life Sciences, is delivering strong and sustained growth in orders for our products.'' The Company plans to release its financial results for the second quarter on Tuesday, July 31, 2001 followed by a conference call at 11:00 a.m. Eastern Time. The Company will provide additional financial information and guidance for the future along with specific industry insights at that time.<< snip Cheers, Tuck